NIFTY 50

IPO of biologics division likely in next few years, says Biocon's Kiran Mazumdar Shaw

Updated : May 15, 2019 11:13 AM IST

Annualised numbers for biologics segment have almost doubled YoY: Biocon
Don't find it reasonable the way biologics business is being looked at: Biocon
Delivered strong growth in biosimilar segment in emerging markets: Biocon

You May Also Like

Live TV